SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

RPG Life Sciences - Quaterly Results

30 Apr 2024 Evaluate
The revenue zoomed 7.17% to Rs. 1269.90 millions for the quarter ended March 2024 as compared to Rs. 1184.90 millions during the corresponding quarter last year.Net Profit recorded in the quarter ended March 2024 rise to 27.92% to Rs. 132.40  millions  compared to R. 103.50 millions in corresponding previous quarter.The company reported a good operating profit of 223.70 millions compared to 177.50 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 1269.90 1184.90 7.17 5820.50 5128.10 13.50 5820.50 5128.10 13.50
Other Income 16.50 18.40 -10.33 72.10 48.00 50.21 72.10 48.00 50.21
PBIDT 223.70 177.50 26.03 1353.60 1074.90 25.93 1353.60 1074.90 25.93
Interest 1.40 0.50 180.00 4.50 3.10 45.16 4.50 3.10 45.16
PBDT 222.30 177.00 25.59 1349.10 1071.80 25.87 1349.10 1071.80 25.87
Depreciation 44.90 38.90 15.42 170.70 155.00 10.13 170.70 155.00 10.13
PBT 177.40 138.10 28.46 1178.40 916.80 28.53 1178.40 916.80 28.53
TAX 45.00 34.60 30.06 301.80 240.40 25.54 301.80 240.40 25.54
Deferred Tax -9.50 -2.30 313.04 -23.60 -3.10 661.29 -23.60 -3.10 661.29
PAT 132.40 103.50 27.92 876.60 676.40 29.60 876.60 676.40 29.60
Equity 132.30 132.30 0.00 132.30 132.30 0.00 132.30 132.30 0.00
PBIDTM(%) 17.62 14.98 17.59 23.26 20.96 10.95 23.26 20.96 10.95

RPG Life Sciences Share Price

2025.85 126.05 (6.63%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×